Literature DB >> 2332017

Efficacy of cyclosporin A for idiopathic pulmonary fibrosis.

M Fukazawa1, M Kawano, S Hisano, K Ueda, K Matsuba.   

Abstract

In an 11-year-old girl with severe dyspnoea and cyanosis, idiopathic pulmonary fibrosis (IPF) was diagnosed. The PaO2 of blood could be maintained between 50 mm Hg and 70 mm Hg with a high dose pulse corticosteroid therapy, although this dose could not be reduced. Azathioprine in addition to prednisolone provoked deterioration. Twelve weeks after admission, cyclosporin A (Cs A), a known immunosuppressant, was started together with prednisolone. The PaO2 reverted to normal within 1 month and prednisolone could be tapered off within 6 months. Two years after admission, the patient is free of symptoms on continuous Cs A therapy. This case seems to be the first case successfully treated with Cs A.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332017     DOI: 10.1007/bf02009669

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  [Treatment of interstitial pneumonia in autoimmune mice with cyclosporin A].

Authors:  H Okudaira; T Ogita; T Miyamoto; J Shiga; M Suko; K Okudaira; E Terada; A Ghoda; K Terada; M Saito
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1984-10

Review 2.  Interstitial lung disease: current concepts of pathogenesis, staging and therapy.

Authors:  R G Crystal; J E Gadek; V J Ferrans; J D Fulmer; B R Line; G W Hunninghake
Journal:  Am J Med       Date:  1981-03       Impact factor: 4.965

3.  Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis.

Authors:  K O'Donnell; B Keogh; A Cantin; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1987-08

4.  Fibrosing alveolitis in infancy and childhood.

Authors:  C J Hewitt; D Hull; J W Keeling
Journal:  Arch Dis Child       Date:  1977-01       Impact factor: 3.791

5.  The effect of cyclosporin A on pulmonary fibrosis induced by butylated hydroxytoluene, bleomycin and beryllium sulfate.

Authors:  L E Sendelbach; R C Lindenschmidt; H P Witschi
Journal:  Toxicol Lett       Date:  1985-08       Impact factor: 4.372

6.  Effect of intermittent high dose parenteral corticosteroids on the alveolitis of idiopathic pulmonary fibrosis.

Authors:  B A Keogh; J Bernardo; G W Hunninghake; B R Line; D L Price; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1983-01

7.  Differentiation between idiopathic pulmonary fibrosis and interstitial pneumonia associated with collagen vascular diseases by comparison of the ratio of OKT4+ cells and OKT8+ cells in BALF T lymphocytes.

Authors:  S Nagai; N Fujimura; T Hirata; T Izumi
Journal:  Eur J Respir Dis       Date:  1985-07

8.  Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine.

Authors:  R H Winterbauer; S P Hammar; K O Hallman; J E Hays; N E Pardee; E H Morgan; J D Allen; K D Moores; W Bush; J H Walker
Journal:  Am J Med       Date:  1978-10       Impact factor: 4.965

9.  Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens.

Authors:  T Hara; L K Jung; J M Bjorndahl; S M Fu
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

  9 in total
  3 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  New strategies for treatment of pulmonary fibrosis.

Authors:  S H Phan
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.